The purpose of this study is to compare the reduction in the number of severe headache days
at six months in people with chronic migraine treated with topiramate and propranolol versus
those treated with topiramate and a placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Anne Lindblad
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Ortho-McNeil Janssen Scientific Affairs, LLC